IceCure Medical Implements Reverse Share Split for Nasdaq Compliance and Growth Strategy

IceCure Medical Implements 1-for-30 Reverse Share Split

On June 2, 2026, IceCure Medical Ltd. (NASDAQ: ICCM), renowned for its innovative minimally-invasive cryoablation technology designed to effectively destroy tumors by freezing, made a major announcement regarding its corporate strategy. The company revealed plans to conduct a 1-for-30 reverse share split of its ordinary shares. This decision aims to ensure compliance with Nasdaq's minimum bid price requirement of $1.00 per share, as part of the company's broader capital markets strategy.

Objective of the Share Split

The reverse share split is primarily designed to boost the trading price of IceCure's ordinary shares, thereby adhering to Nasdaq's listing requirements. As of now, the company has until November 9, 2026, to rectify the non-compliance issue. Through this strategic maneuver, IceCure hopes to not only uphold its listing but also to strengthen its market position.

The reverse split was approved during a Special General Meeting of Shareholders held on May 11, 2026. The board of directors has set the split based on a predetermined ratio, and the shares will commence trading on a split-adjusted basis starting June 4, 2026. Post-split, the CUSIP number for the shares will change to M53071201.

Impact on Shareholders

The reverse split will uniformly affect all shareholders, adjusting the number of issued and outstanding ordinary shares from approximately 84.2 million to around 2.8 million. However, this change will not affect the percentage ownership of existing shareholders, with minor adjustments made only for fractional shares. Additionally, adjustments will also apply to shares tied to options and warrants, ensuring coherence across the company's equity structure.

The company’s transfer agent, VStock Transfer, will provide guidelines to shareholders regarding the exchange of share certificates, ensuring a smooth transition to the new share structure. Shareholders holding their investments in book-entry form, brokerage accounts, or